Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that
20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this open-label study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.

开始日期2024-10-01

申办/合作机构

University of Michigan

[+1]

NCT06626152 / Recruiting临床2期IIT

Measuring Psychomotor Response to L-DOPA Challenge As a Biomarker for Outcomes in Late-Life Depression: a Pilot Feasibility Trial

Background
Adults over the age of 60 with symptoms of major depressive disorder are said to have late-life depression (LLD), a condition that usually decreases a person's quality of life and is associated with other risks like physical frailty and dementia. A common feature of more severe LLD is psychomotor slowing, where a person's ability to think and move are impaired. For example, they might not be able to walk or process information as quickly, and they might have problems with their working memory.
Psychomotor slowing in LLD might be the result of a problem with the way a person's body produces or responds to the neurotransmitter dopamine. The drug Levodopa (L-DOPA), which can replace missing dopamine in the brain, has been used to treat to treat Parkinson's disease for many decades, and it might also affect psychomotor slowing in LLD.
Methods
In this study, participants are adults aged 60 years or older with moderate to severe major depression. Participants undergo the "L-DOPA challenge"-a 2-week period where they receive a dose of L-DOPA once a day for the first week and a dose of L-DOPA twice a day for the second week. Before and after a participant completes the L-DOPA challenge, the study team assesses their depressive symptoms and psychomotor function. After the L-DOPA challenge, if a participant still shows signs of moderate or severe depression, they receive an antidepressant for 12 weeks.
Aims
The first aim of this study is to test the feasibility of the L-DOPA challenge-that is, whether most of the 50 participants recruited for this study will complete the L-DOPA challenge. For example, participants might have to withdraw if they can't make the daily visits to the research site to receive their L-DOPA medication, if they can't tolerate the medication's side effects, or if their depressive symptoms get significantly worse. Our hypothesis is that 80% of the participants will complete the L-DOPA challenge.
The second aim of the study is to see if L-DOPA affects participants' depressive symptoms, processing speed, and working memory. Our hypothesis is that L-DOPA response, measured as an improvement in gait speed, is associated with a decrease in depressive symptoms and an increase in processing speed and working memory.

开始日期2024-08-15

申办/合作机构

University of British Columbia

[+1]

NCT06219915 / Completed临床1/2期IIT

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System

Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that
20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs in this double-blinded, placebo-controlled study using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.

开始日期2024-03-15

申办/合作机构

University of Michigan

[+1]

100 项与卡比多巴相关的临床结果

登录后查看更多信息

100 项与卡比多巴相关的转化医学

登录后查看更多信息

100 项与卡比多巴相关的专利（医药）

登录后查看更多信息

2,795

项与卡比多巴相关的文献（医药）

2024-12-01·Fortschritte der Neurologie-Psychiatrie

Synergien statt Rivalitäten – die missverstandenen Rollen von kontinuierlicher intrajejunaler Levodopatherapie und Tiefer Hirnstimulation in der Behandlung des Morbus Parkinson – eine Expertenmeinung

Review

作者: Groppa, Sergiu ; Jost, Wolfgang H. ; Coenen, Volker ; Rijntjes, Michel ; Sajonz, Bastian ; Schröter, Nils

2024-12-01·BIOMEDICINE & PHARMACOTHERAPY

Article

作者: Manjarrez, Elias ; Moreno-Castillo, Mayra ; Guertin, Pierre A

2024-12-01·JOURNAL OF NEUROLOGY

Review

作者: Brockmann, Kathrin ; Outeiro, Tiago ; Klebe, Stephan ; Kassubek, Jan ; Claßen, Joseph ; Hilker-Roggendorf, Rüdiger ; Neumann, Manuela ; Fimm, Bruno ; Rieß, Olaf ; Witt, Jonas L. ; Fanciulli, Alessandra ; Woitalla, Dirk ; Jost, Wolfgang ; Walter, Uwe ; Kuhlenbäumer, Gregor ; Winkler, Christian ; Bähr, Mathias ; Klietz, Martin ; Ebersbach, Georg ; Löhle, Matthias ; Berg, Daniela ; Köglsperger, Thomas ; Mollenhauer, Brit ; Trenkwalder, Claudia ; van Eimeren, Thilo ; Meyer, Philipp T. ; Reetz, Kathrin ; Maaß, Sylvia ; Folkerts, Ann-Kristin ; Krismer, Florian ; Ceballos-Baumann, Andrés ; Zeuner, Kirsten ; Höllerhage, Matthias ; Sixel-Döring, Friederike ; Dodel, Richard ; Seppi, Klaus ; Buhmann, Carsten ; Hasan, Alkomiet ; Hopfner, Franziska ; Deuschl, Cornelius ; Loewenbrück, Kai ; Warnecke, Tobias ; Reese, René ; Gausepohl, Madeleine ; Pötter-Nerger, Monika ; Klein, Christine ; Deuschl, Günther ; Wegner, Florian ; Eggers, Carsten ; Witt, Karsten ; Kühn, Andrea ; Ruf, Viktoria ; Menzel, Regina ; Schneider, Anja ; Odin, Per ; Becktepe, Jos ; Krack, Paul ; Bantel, Martina ; Hermann, Wiebke ; Wächter, Tobias ; Höglinger, Günter ; Lorenzl, Stefan ; Schnitzler, Alfons ; Levin, Johannes ; Lingor, Paul ; Tönges, Lars ; Schrader, Christoph ; Kalbe, Elke ; Storch, Alexander ; Maetzler, Walter ; Liepelt-Scarfone, Inga

243

项与卡比多巴相关的新闻（医药）

2024-12-04

·PRNewswire

Mitsubishi Tanabe Pharma America to Present Data on Investigational ND0612 at the 2024 Annual Meeting of the Parkinson Study Group

JERSEY CITY, N.J., Dec. 4, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of two abstracts on investigational ND0612 in Parkinson's disease (PD) at the 2024 Annual Meeting of the Parkinson Study Group (PSG), being held December 5-8 in Nashville, Tenn. ND0612 is being evaluated as a 24-hour, continuous, subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD). "We look forward to attending the PSG meeting where we will discuss our latest findings on investigational ND0612 with other experts from the scientific community," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs, MTPA. "This ongoing research is driven by our passion to support the Parkinson's disease community and continue investigating areas of significant unmet needs for patients." MTPA's posters will be presented in Grand Hall A, B & C on December 5, 5:00 p.m.-7:00 p.m. CST: Presentation Details: Presentations will discuss outcomes from the open-label, Phase 2b BeyoND study (NCT02726386), which evaluated the safety and efficacy of investigational ND0612 over three years in people with PD experiencing motor fluctuations, as well as a characterization of infusion site reactions (ISRs) reported from treatment with ND0612 in clinical studies. Continuous Subcutaneous Levodopa/Carbidopa Infusion with ND0612 for Parkinson's Disease: Three-Year Data from the Open-Label BeyoND Study (Jonathan Pereira, M.D.; MTPA) Characterization of Infusion Site Reactions (ISRs) with 24-Hour Subcutaneous Infusion of ND0612: Findings from an Integrated Safety Database (Jonathan Pereira, M.D.; MTPA) About ND0612 ND0612 is an investigational drug-device combination therapy – a 24-hours/day, continuous subcutaneous (SC) infusion of liquid levodopa/carbidopa (LD/CD) for the treatment of motor fluctuations in people with Parkinson's disease (PD). Development of investigational ND0612 is being led by NeuroDerm, Ltd., a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). About Mitsubishi Tanabe Pharma America, Inc. Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC). It was established by MTPC to develop and advance our pipeline as well as commercialize approved pharmaceutical products in North America. For more information, please visit or follow us on X (formerly Twitter), Facebook and LinkedIn. About Mitsubishi Tanabe Pharma Corporation Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan's pharmaceutical industry. MTPC sets the MISSION of "Creating hope for all facing illness". To that end, MTPC is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney, and cancer. MTPC is focusing on "precision medicine" to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety. In addition, MTPC is working to develop "around the pill solutions" to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to About NeuroDerm, Ltd. NeuroDerm, Ltd. is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), based in Israel, inspired to reduce disease burden and improve the quality of life of patients and their families through innovative drug-device combination therapies and technologies. NeuroDerm is an integrated pharmaceutical and medical technology company developing central nervous system (CNS) product candidates. For additional information, please visit NeuroDerm's website at or follow the Company on LinkedIn. Media inquiries: [email protected] SOURCE Mitsubishi Tanabe Pharma America WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床2期

2024-12-03

·药智网

瞄准帕金森！复星医药又一动作

近日，据CDE官网公示，复星医药和Bial-Portela&Ca公司共同申报的5.1类新药奥吡卡朋胶囊的上市申请获得受理。资料显示，奥吡卡朋胶囊是一款复星医药从葡萄牙Bial-Portela&Ca公司引进的原发性帕金森病辅助治疗药物，为新一代的儿茶酚-氧位-甲基转移酶抑制剂（COMT）抑制剂。值得一提的是，目前国内已获批上市的COMT抑制剂包括一代的托卡朋和二代的恩他卡朋。相比以上同类药物，第三代COMT抑制剂奥吡卡朋在有效性和安全性等方面表现出优势。 01 复星引进，有望国内上市目前，全球共三种COMT抑制剂上市，国内上市的COMT抑制剂包括托卡朋和恩他卡朋，此外有恩他卡朋与复方左旋多巴组合的恩他卡朋双多巴片获批上市，复星医药引进的奥吡卡朋胶囊已在国内递交上市申请。表1 COMT抑制剂竞争格局资料来源：药智数据、药智咨询整理（1）托卡朋（Tolcapone）由罗氏、Valeant和Meda联合研发，是全球首款获批上市的COMT抑制剂，于1997年8月获EMA批准，之后于1998年1月获FDA批准上市，商品名为Tasmar。托卡朋被收录于《中国帕金森病治疗指南（第四版）》早期帕金森病的症状治疗，对症状波动的治疗被评估为有效，临床可能有用。值得注意的是，托卡朋具有较强肝毒性，可能导致患者严重的、致命的、急性的肝细胞损害，目前临床已很少使用。（2）恩他卡朋（Entacapone）由Orion Pharma和诺华联合开发，于1998年9月获EMA批准，之后于1999年10月获得FDA批准上市，商品名分别为Comtess和Comtan。恩他卡朋通过抑制COMT酶减少左旋多巴代谢，增加了脑内可利用的左旋多巴总量，作为标准疗法左旋多巴/苄丝肼或左旋多巴/卡比多巴的辅助疗法，用于治疗标准疗法无法稳定地帕金森病及有开－关波动症状的成年患者。此外有由Orion Pharma开发的卡比多巴/左旋多巴/恩他卡朋组合药物恩他卡朋双多巴片于2003年首次获得FDA批准上市，用于治疗帕金森病，商品名为Stalevo。恩他卡朋于2009年在中国获批上市，商品名为珂丹，用于帕金森病的辅助治疗，且在同年便被纳入国家医保目录。恩他卡朋上市后销售额逐年上升，药智数据显示，2023年恩他卡朋片国内销售额达到2亿元人民币。（3）奥吡卡朋是葡萄牙Bial-Portela研发的一款COMT抑制剂，于2016年6月被EMA批准用于帕金森病的辅助治疗。2020年，奥吡卡朋获美国FDA批准上市，作为左旋多巴/卡比多巴的辅助疗法。 2018年，复星医药成员企业万邦医药与Bial-Portela&Ca订立协议，万邦医药将在中国大陆地区独家销售代理奥吡卡朋。2024年11月14日，复星医药和Bial-Portela&Ca公司共同申报的奥吡卡朋胶囊的上市申请获得受理。 02 具有明显优势，或成为新一轮迭代帕金森病是一种常见的中老年神经系统退行性疾病，临床主要表现为震颤、肌强直、动作迟缓、姿势平衡障碍的运动症状和睡眠障碍、嗅觉障碍、自主神经功能障碍、认知和精神障碍等非运动症状。流行病学调查研究显示欧美国家60岁以上帕金森病患病率达到1%，80岁以上超过4%，我国65岁以上人群患病率为1.7%。帕金森病药物治疗的目标包括达到有效改善症状、避免或降低不良反应、提高工作能力和生活质量，用药坚持“剂量滴定”以避免产生药物急性不良反应，力求实现“尽可能以小剂量达到满意临床效果”的用药原则，避免或降低运动并发症尤其是异动症的发生率。目前临床上治疗帕金森病的药物主要包括：复方左旋多巴、多巴胺受体激动剂、MAO-B抑制剂、COMT抑制剂、抗胆碱能药和金刚烷胺。左旋多巴是治疗帕金森病的标准疗法外源性左旋多巴被人体吸收后进入大脑转化为多巴胺，增强神经元活性，重新达到大脑神经递质的平衡，是帕金森病药物治疗中最有效的对症治疗药物。然而，很大一部分的左旋多巴会被人体外周组织的儿茶酚-O-甲基转移酶（CMOT）催化形成3-氧-甲基多巴，直接在颅脑外周组织起作用，大部分未能成功进入脑内，导致在大多数患者中，随着疾病进展和左旋多巴长期使用会产生运动并发症，包括症状波动和异动症，与左旋多巴的治疗时间相比，高剂量的左旋多巴和长病程对异动症的发生风险影响更大。儿茶酚-O-甲基转移酶抑制剂（COMT抑制剂）主要作用于外周的COMT，通过抑制COMT酶的活性，减少左旋多巴在外周组织代谢为3-O-甲基多巴(3-OMD)，更大程度透过血脑屏障进入大脑，增加患者脑内可利用的左旋多巴的总量，延长和增加左旋多巴的生物利用度，从而延长左旋多巴的作用时间并减少左旋多巴的用量。目前COMT抑制剂可分为三代药物。第一代COMT抑制剂托卡朋由于其肝毒性目前临床已很少使用；第二代COMT抑制剂恩他卡朋未发现明显的肝毒性，安全性更高，临床使用更多，是目前国内帕金森治疗的常用一线药物；第三代COMT抑制剂奥吡卡朋，其在药代动力学、药效和安全性上相比上一代药物又具备更多优势。奥吡卡朋对COMT的抑制作用显著且持久。研究显示，奥吡卡朋诱导的S-COMT抑制显示半衰期超过100小时，使其适合每日一次的用药方案；相比恩他卡朋在用药后5～7小时，COMT活性即恢复至基线水平，每日需多次服药。其他研究显示奥吡卡朋在「关期」和「开期」时间、临床/患者总体印象变化、非运动症状等多个帕金森病治疗有效性指标上，相比恩他卡朋表现出明显的优势。 03 结语儿茶酚-氧位-甲基转移酶抑制剂（COMT）抑制剂是目前国内外帕金森病治疗指南明确推荐的辅助治疗药物。目前国内COMT抑制剂市场为第二代药物恩他卡朋占据。第三代COMT抑制剂奥吡卡朋在药代动力学和有效性方面均优于上一代药物，如成功获批上市或将推动国内COMT抑制剂新一轮迭代。声明：本内容为作者独立观点，不代表药智网立场。如需转载，请务必注明文章作者和来源。对本文有异议或投诉，请联系maxuelian@yaozh.com。责任编辑 | 八角转载开白 | 马老师 18996384680（同微信）如需定制医药咨询服务，请扫描下方二维码咨询！阅读原文，是受欢迎的文章哦

上市批准

2024-12-02

·药渡Daily

国内帕金森患者再添新选择，沙非胺片获批上市

今日（12月2日），从NMPA官网最新公示，帕金森病治疗新药甲磺酸沙非胺片获批上市，从药渡数据检索可知，沙非胺（沙芬酰胺，Safinamide）最早于2015年在欧洲获批，2017年获FDA批准上市，成为10多年来在美国首个获批用于治疗帕金森病的新化学实体，适应症：作为左旋多巴/卡比多巴的辅助治疗,处于“关闭”期的帕金森症。从作用机制来看，沙非胺属于第三代单胺氧化酶B（MAO-B）抑制剂，与第1、2代MAO-B抑制剂相比，沙非胺对MAO-B的选择性更高，且作用可逆，停药8小时后，MAO-B的生理活性可以完全恢复。沙非胺在中国患者中的临床III期试验XINDI研究已于2022年11月8日在CNS Drugs上发表。此项研究是一项III期、随机、双盲、安慰剂对照、多中心临床研究，旨在评价沙非胺作为联合治疗，用于接受稳定剂量左旋多巴治疗的、出现运动波动的特发性帕金森病的中国患者的疗效和安全性。研究主要临床终点为平均每日总“关”期时间自基线至第16周的变化。次要疗效终点为平均每日总“开”期时间、统一帕金森病评定量表（UPDRS）、数字评定量表（NRS）、临床总体印象量表（CGI）和帕金森病问卷-39项量表（PDQ-39）自基线至第16周的变化，以及不良事件（AE）和严重不良事件（SAE）等安全性指标。研究结果表明，在第16周，沙芬酰胺组和安慰剂组之间平均每日总“关”期时间变化的差异为1.10小时（p<0.0001）。并且从第2周开始沙芬酰胺组每日总“关”期时间的变化就体现了明显优势，提示沙芬酰胺可在短期内起效。除了改善“关”期时间外，沙芬酰胺组在延长“开”期时间，改善UPDRS、CGI和PDQ-39评分方面相较于安慰剂均有显著优势，疗效明确。参考文献 NMPA官网帕金森病治疗新药 [沙芬酰胺 Xadago] 中国III期临床研究结果发表！药渡数据

临床3期上市批准

100 项与卡比多巴相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00558	卡比多巴	N04BA03	DB00190

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
恶心	美国	Aton Pharma, Inc.	1977-04-25
帕金森病	美国	Aton Pharma, Inc.	1977-04-25
脑炎后帕金森病	美国	Aton Pharma, Inc.	1977-04-25
继发性帕金森病	美国	Aton Pharma, Inc.	1977-04-25
呕吐	美国	Aton Pharma, Inc.	1977-04-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02553265 (CarbiFD, CTgov)	临床2期	单纯自主神经功能衰竭 \| 家族性自主神经功能异常	22	Placebo (Placebo)	夢鹹遞餘廠獵糧願製鏇(獵鬱鹽築選觸鬱膚齋齋) = 窪遞憲膚選觸遞鏇選膚衊餘鏇築遞顧廠襯蓋選 (觸餘鹽構願鹽襯廠鬱製, 夢製蓋鏇遞願夢廠廠壓 ~ 衊壓構願範積糧積簾憲) 更多	-	2022-02-09
				Carbidopa Low-Dose (Low-Dose Carbidopa)	夢鹹遞餘廠獵糧願製鏇(獵鬱鹽築選觸鬱膚齋齋) = 願選醖鹹襯膚膚餘選網衊餘鏇築遞顧廠襯蓋選 (觸餘鹽構願鹽襯廠鬱製, 醖築網遞窪鹹獵築憲範 ~ 糧構糧積鬱製淵觸糧壓) 更多
NCT00685919 (CTgov)	临床2/3期	体位性心动过速综合征	32	Placebo (Healthy Participants Who Received Placebo as Treatment A or Treatment B)	鹽鏇膚餘壓鏇鹽觸憲蓋(艱製繭膚餘選顧鏇選簾) = 窪壓醖夢餘廠蓋繭觸醖廠範襯夢構淵鹹壓夢鹹 (願製艱憲夢鹽夢齋遞繭, 膚網鏇衊淵選構憲鹽鏇 ~ 衊艱範鹽網觸獵夢餘網) 更多	-	2021-09-20
				Carbidopa (Healthy Participants Who Received Carbidopa as Treatment A or Treatment B)	鹽鏇膚餘壓鏇鹽觸憲蓋(艱製繭膚餘選顧鏇選簾) = 鹹積遞膚構遞淵顧廠夢廠範襯夢構淵鹹壓夢鹹 (願製艱憲夢鹽夢齋遞繭, 繭網築獵憲積積範鹹鹹 ~ 繭構糧壓衊顧窪夢繭製) 更多
AAN2020	N/A	帕金森病	23	CVT-301 84mg with CD 25mg	鑰簾鏇積醖製鹽衊鹹鬱(糧壓遞築夢窪壓積窪觸) = 7 (30.4%) in the CVT-301 group vs 1 (4.5%) subject administered oral CD/LD 選顧積築鏇願鏇鬱淵築 (簾艱衊襯衊齋夢蓋構願 )	积极	2020-04-14
				Oral CD/LD 25/100mg
NCT03115827 (CTgov)	临床4期	帕金森病	15	Carbidopa+Droxidopa	顧齋醖壓衊築齋積鬱淵(膚糧鬱網鹽構衊醖艱願) = 顧窪膚網襯繭糧獵鏇鹽願鬱憲夢憲夢繭範鹽獵 (齋窪廠鏇齋壓襯艱願衊, 襯艱鹽製廠選窪製築夢 ~ 鑰獵壓窪齋鹽醖鹽獵鏇) 更多	-	2020-01-27
NCT01766258 (Pubmed \| Ann Neurol)	临床2期	帕金森病	117	ODM-101/65	餘鏇壓壓襯繭積衊獵願(齋顧構顧願膚鹹窪選範) = Treatment-related serious adverse events were blood creatine kinase increase (LCE) 願鬱齋顧憲築糧鹹鏇築 (廠夢網糧醖構壓繭夢顧 ) 更多	-	2019-03-26
				ODM-101/105
MDS2018	N/A	高同种半胱胺酸血症 INR \| D-dimer \| homocysteine	-	Levodopa/carbidopa intestinal gel (LCIG)	網獵鬱築夢築選襯鏇夢(簾壓襯鹽鑰簾鹽願窪製) = 選夢糧壓壓積壓齋簾鑰築壓繭獵夢遞構積衊蓋 (觸簾積淵衊鬱齋膚鑰膚 ) 更多	-	2018-10-05
SNMMI2017	N/A	胰岛素瘤	26	18F]FDOPA PET/CT with contrast enhancement and without carbidopa premedication	醖壓製齋築網壓齋鹹簾(醖鬱艱襯遞鹽鑰齋繭製) = 廠蓋鹽鑰艱顧積構遞製繭艱襯範鹽顧廠築醖獵 (範鏇顧齋構繭繭窪壓築 )	积极	2017-05-24
AAN2014	N/A	高血压	15	Carbidopa	餘糧餘獵積築齋餘獵獵(憲憲顧膚鹽醖齋鹹憲醖) = 構壓壓鏇艱遞簾鹽鬱糧鑰鹹窪繭壓網構願窪襯 (願壓廠齋觸製鬱窪鑰鏇 ) 更多	-	2014-04-08